Two pharmaceutical companies are locked in a legal battle over the patent for an anti-cancer drug, with one claiming the patent was altered in order to catch it out.Aventis Pharma SA has applied for an interim order restraining InterPharma (NZ) from suppl
Niko Kloeten Thu, 29 Apr 2010
Two pharmaceutical companies are locked in a legal battle over the patent for an anti-cancer drug, with one claiming the patent was altered in order to catch it out.
Aventis Pharma SA has applied for an interim order restraining InterPharma (NZ) from supplying the product Docetaxel Ebewe to Pharmac,
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
